Abstract
Waldenström’s macroglobulinemia (WM) is a distinct B-cell lymphoproliferative disorder for which clearly defined criteria for the diagnosis, initiation of therapy, and treatment strategy have been proposed as part of the consensus panels of the International Workshops on WM (IWWM). Therapeutic strategies in WM should be based on individual patient and disease characteristics. Chemoimmunotherapy combinations with rituximab (R) and cyclophosphamide/dexamethasone (DRC) or bendamustine (Benda-R) or bortezomib/dexamethasone (BDR) provide durable responses and are still indicated in most patients. The approval of the BTK-inhibitor ibrutinib in the USA and in Europe represents a novel and effective treatment option for both treatment-naïve and relapsing patients. Other BCR inhibitors, second-generation proteasome inhibitors (e.g., carfilzomib), and mTOR inhibitors are promising and may expand future treatment options. This chapter summarizes the treatment strategies in WM patients with the treatment options widely described by previous authors.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Dimopoulos MA, Kastritis E, Owen RG, Kyle RA, Landgren O, Morra E, et al. Treatment recommendations for patients with Waldenström’s Macroglobulinemia (WM) and related disorders: consensus from the Seventh International Workshop on WM. Blood. 2014;124(9):1404–11.
Dimopoulos MA, Trotman J, Tedeschi A, et al. Ibrutinib therapy in rituximab-refractory patients with Waldenström’s macroglobulinemia: initial results from an international, multicenter, open-label phase 3 substudy (INNOVATETM). Blood. 2015;126: Abstract 2745.
Gertz MA, Anagnostopoulos A, Anderson K, et al. Treatment recommendations in Waldenstrom’s macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom’s Macroglobulinemia. Semin Oncol. 2003;30(2):121–6.
Treon SP, Gertz MA, Dimopoulos M, et al. Update on treatment recommendations from the Third International Workshop on Waldenstrom’s macroglobulinemia. Blood. 2006;107(9):3442–6.
Kyle RA, Treon SP, Alexanian R, et al. Prognostic markers and criteria to initiate therapy in Waldenstrom’s macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom’s Macroglobulinemia. Semin Oncol. 2003;30(2):116–20.
Buske C, Leblond V. How to manage Waldenstrom’s macroglobulinemia. Leukemia. 2013;4:762–72.
Buske C, Leblond V, Dimopoulos M, Kimby E, Jäger U, Dreyling M. ESMO Guidelines Working Group. Waldenstrom’s macroglobulinaemia: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013;Suppl 6:vi155-9.
Treon SP. How I treat Waldenstrom’s macroglobulinemia. Blood. 2015;126:721–32.
Furman R, Bilotti E, Graef T. Single-agent ibrutinib demonstrates long-term activity and safety in patients with relapsed/refractory Waldenstrom’s macroglobulinemia. Proc Eur Hematol Assoc. 2015; Abstract 1786.
Buske C, Seymour J. Immunochemotherapy in Waldenström macroglobulinemia: still the backbone of treatment. Leuk Lymphoma. 2015;9:1–6.
Dimopoulos MA, Gertz MA, Kastritis E, et al. Update on treatment recommendations from the Fourth International Workshop on Waldenstrom’s Macroglobulinemia. J Clin Oncol. 2009;27(1):120–6.
Treon SP, Tripsas CK, Meid K, Warren D, Varma G, Green R, et al. Ibrutinib in previously treated Waldenstrom macroglobulinemia. N Engl J Med. 2015;372:1430–40.
Leblond V, Kastritis E, Advani R, Ansell SM, Buske C, Castillo JJ, et al. Treatment recommendations for Waldenström macroglobulinemia from the Eighth International Workshop on WM. Blood. 2016. pii: blood-2016-04-711234. [Epub ahead of print].
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2017 Springer International Publishing Switzerland
About this chapter
Cite this chapter
Leblond, V., Dimopoulos, M.A., Treon, S.P. (2017). Treatment Recommendations in Waldenström Macroglobulinemia. In: Leblond, V., Treon, S., Dimoploulos, M. (eds) Waldenström’s Macroglobulinemia. Springer, Cham. https://doi.org/10.1007/978-3-319-22584-5_26
Download citation
DOI: https://doi.org/10.1007/978-3-319-22584-5_26
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-22583-8
Online ISBN: 978-3-319-22584-5
eBook Packages: MedicineMedicine (R0)